Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Atlantis Eyecare

Neither a doctor nor a teaching hospital

Research payments

$1,057,451

18 payments

Through program year 2025, Atlantis Eyecare is reported as receiving $1,057,451 in research payments, across 18 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,822 2
2024 Research $9,750 2
2023 Research $34 1
2022 Research $3,500 1
2020 Research $780,415 4
2019 Research $261,930 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,010,413 6 payments
  2. Aerie Pharmaceuticals, Inc. $28,601 3 payments
  3. Johnson & Johnson Surgical Vision, Inc. $7,250 1 payment
  4. EyePoint Pharmaceuticals US, Inc. $6,000 2 payments
  5. Ocular Therapeutix, Inc. $1,822 2 payments
  6. Alimera Sciences, Inc. $1,400 1 payment
  7. Novo Nordisk AS $1,165 1 payment
  8. Allergan Inc. $800 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $536,227 2 payments
  2. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $443,209 2 payments
  3. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $30,977 2 payments
  4. A Multicenter, Open-Label Study of Rhopressa (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma Or Ocular Hypertension in A Real-World Setting $28,601 3 payments
  5. A Clinical Study Comparing Postoperative Outcomes Between the TECNIS Eyhance Toric II Intraocular Lens with TECNIS Simplicity Delivery System, Model Series DIU and the TECNIS Synergy Toric II Intraocular Lens with TECNIS Simplicity Delivery System, Model $7,250 1 payment
  6. Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (EYP-DIP-001) $3,500 1 payment
  7. A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract $2,500 1 payment
  8. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $1,822 2 payments
  9. Paladin $1,400 1 payment
  10. Nn9535-4352 $1,165 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record